TY - JOUR
T1 - Her-2/neu expression in ovarian cancer
T2 - Pre- and postexposure to platinum chemotherapy
AU - Peethambaram, Prema P.
AU - Cliby, William A.
AU - Lubiniecki, Gregory
AU - Clayton, Amy C.
AU - Roche, Patrick C.
AU - Iturria, Stephen J.
AU - Hartmann, Lynn C.
AU - Hellström, Ingegerd
AU - Strome, Scott E.
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Objective. Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy. Methods. Tissue samples from 43 patients who had surgery for ovarian cancer between 1991 and 2001 at the Mayo Clinic were stained for Her-2/neu expression using the DAKO kit and reviewed independently by two pathologists. Patient charts were reviewed for demographic data, clinical course, chemotherapy, and survival times. Results. Her-2/neu expression was 0 in 30 patients (69.76%), 1+ in 12 patients (27.9%), and 3+ in 1 patient (2.32%) before chemotherapy. After platinum chemotherapy, Her-2/neu expression changed from 0 to 1+ in 7 patients, from 1+ to 0 in 4 patients, 0 to 2+ in 1 patient, and 1+ to 2+ in 2 patients and no change was seen in 29 patients. Both pathologists agreed in all instances when the score was 0 or 1+ and disagreed in two instances between a negative and a weakly positive staining. Conclusions. Our findings indicate a low level of overexpression of Her-2/neu at the time of primary diagnosis of epithelial ovarian cancer. Relapsing tumors show no significant change in the intensity of Her-2/neu expression after platinum-based chemotherapy. Further prospective studies are needed to confirm these findings and to ascertain whether platinum chemotherapy indeed has no effect on Her-2/neu expression.
AB - Objective. Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy. Methods. Tissue samples from 43 patients who had surgery for ovarian cancer between 1991 and 2001 at the Mayo Clinic were stained for Her-2/neu expression using the DAKO kit and reviewed independently by two pathologists. Patient charts were reviewed for demographic data, clinical course, chemotherapy, and survival times. Results. Her-2/neu expression was 0 in 30 patients (69.76%), 1+ in 12 patients (27.9%), and 3+ in 1 patient (2.32%) before chemotherapy. After platinum chemotherapy, Her-2/neu expression changed from 0 to 1+ in 7 patients, from 1+ to 0 in 4 patients, 0 to 2+ in 1 patient, and 1+ to 2+ in 2 patients and no change was seen in 29 patients. Both pathologists agreed in all instances when the score was 0 or 1+ and disagreed in two instances between a negative and a weakly positive staining. Conclusions. Our findings indicate a low level of overexpression of Her-2/neu at the time of primary diagnosis of epithelial ovarian cancer. Relapsing tumors show no significant change in the intensity of Her-2/neu expression after platinum-based chemotherapy. Further prospective studies are needed to confirm these findings and to ascertain whether platinum chemotherapy indeed has no effect on Her-2/neu expression.
UR - http://www.scopus.com/inward/record.url?scp=0037384127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037384127&partnerID=8YFLogxK
U2 - 10.1016/S0090-8258(03)00065-9
DO - 10.1016/S0090-8258(03)00065-9
M3 - Article
C2 - 12694661
AN - SCOPUS:0037384127
SN - 0090-8258
VL - 89
SP - 99
EP - 104
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -